Synspira Therapeutics Inc, a clinical-stage biopharmaceutical company that says that it is dedicated to improving the lives of people with cystic fibrosis and other rare diseases, announced on Wednesday that it has signed a contract with Cystic Fibrosis Foundation.

The agreement has been signed to support the development of SNSP003, Synspira's orally delivered non-porcine enzyme replacement therapy intended to treat Malabsorption Syndromes.

The product is a rationally designed treatment including a precise combination of three purified enzymes (lipase, protease and amylase). It is claimed to have the potential to improve clinical results and also to dramatically decrease treatment burden by improving dosing convenience and offering a formulation for paediatric and adult patients unable to swallow capsules.

Synspira's oral enzyme delivery technology is expected to provide a significant advancement over current porcine-based pancreatic enzyme replacement therapies (PERT).